The main aim of the betaJUDO project is to develop innovative therapeutic strategies by increasing pharmacology-based alternatives targeting insulin hypersecretion for the treatment of young obese individuals. Evaluation will de done of current and novel therapies of intervention for their effect on counteracting insulin hypersecretion to halt destruction and facilitate recovery of functionally impaired beta-cells and brown adipocytes. Clinical characterization including validation of novel genetic variants of the young obese individuals belonging to different European cohorts and a well characterized cell model of dysfunction with isolated human palmitate-treated islets will form the basis of the translational work, where principles of reduction of insulin hypersecetion will be mechanistically dissected in the human islets and then tested in the human.  

This is a Collaborative Project of the European FP7-HEALTH.2011.2.4.3-2 program.